Uzbekistan Brings Together the International Community at the UN to Strengthen the Fight Against Childhood Cancer
29.9.2025 11:59:00 EEST | Business Wire | Press release
For the first time in the history of the United Nations General Assembly, Uzbekistan held a special event dedicated to “A global movement to improve survival and reduce suffering for children with cancer and other catastrophic diseases”.
The event was hosted by the Government of Uzbekistan, WHO, St. Jude Children’s Research Hospital and Zamin Foundation.
The event was attended by the First Ladies of Azerbaijan, Angola, Vietnam, Guatemala, Serbia, and Türkiye, the spouse of the Prime Minister of Lebanon, the Director-General of WHO, the President of ECOSOC, the President and leadership of St. Jude Children’s Research Hospital, as well as the Ministers of Health of Angola, Armenia, Bangladesh, Mozambique, the Dominican Republic, Nigeria, Kazakhstan, Qatar, the Republic of the Congo, Kyrgyzstan, Malta, Mongolia, the UAE, Peru, Tajikistan, Timor-Leste, Tuvalu, Türkiye, Chad, and Jamaica, along with representatives of healthcare authorities of Hungary, Indonesia, Russia and Tanzania, international organizations, experts and civil society representatives.
The event showcased the results of the Global Initiative for Childhood Cancer and the Global Platform for Access to Childhood Cancer Medicines. Participants reaffirmed their commitment to achieving a 60% survival rate for children with cancer by 2030 through the development of equitable, integrated and locally resourced health systems.
In her address to the participants of the event, chair of the Board of Trustees of the Zamin Foundation Ziroat Mirziyoyeva mentioned:
"Currently, more than 2 billion children worldwide are at risk or suffer from non-communicable diseases. That is almost a third of the world's population. Millions of them are fighting cancer. Despite the achievements of modern medicine, survival rates remain uneven: in developed countries, they are above 80%, while in developing countries, they are below 30%. This is an unacceptable gap. We are obliged to take steps in order to prevent this tragedy!"
In his address, Director-General of the World Health Organization Dr. Tedros Adhanom Ghebreyesus underlined emphasized: “Every child suffering from cancer deserves an equal right to fight for their life, regardless of the country or community they come from. That is why we launched the WHO Global Initiative for Childhood Cancer. The results speak for themselves: the program has helped more than 400 thousand children in 80 low- and middle-income countries”.
Speaking at the event, St. Jude Children’s Research Hospital President James R. Downing stated: “To fulfill our promise that no child should die at the dawn of life, we are laying the foundations of the Global Sickle Cell Disease Initiative, aimed at improving survival rates among children with this condition. I call on every United Nations member state to join both global initiatives. This must become a priority for all countries”.
Children affected by these diseases became special guests of the event. Their touching stories deeply resonated with the participants. From Uzbekistan, young graduate and volunteer of Mehrli maktab, Samira Idrisova, shared her journey.
Uzbekistan is actively contributing to the global movement for children’s health. In recent years, the country has implemented large-scale programs to reduce child cancer mortality, mobilized additional resources, introduced new standards for diagnosis and treatment, and expanded access to medicines.
The country has adopted the National Strategy to Combat Childhood Cancer for 2025–2030, aligned with the WHO’s CureAll framework. The strategy envisions raising the early detection rate to 65%, increasing one-year survival from 34% to 90%, five-year survival to 60%, and ensuring 100% access to specialized multidisciplinary care.
Moreover, an International Academic Hub for Childhood Cancer has been established in Tashkent aimed at facilitating the integration of international standards in diagnostics, specialist training, and innovation, as well as the exchange of best practices and the development of modern clinical research.
The event became an important international platform for the exchange of expertise, demonstration of solidarity and promotion of innovative solutions in addressing one of the most pressing and often underestimated challenges in global healthcare.
The discussion continued with panel sessions focused on sustaining progress in childhood cancer treatment and implementing the global initiative to combat sickle cell anemia.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250926977972/en/
Contacts
For more information, please contact:
Elena Ikaeva
Director of the Department on media and public relations, IPF Zamin
Phone: +998 712052525
+998 935645050
E-mail: e.ikaeva@zaminfoundation.ngo
https://zaminfoundation.ngo/en/about -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fzaminfoundatio
n.ngo%2Fen%2Fabout&esheet=54330372&newsitemid=20250926977972&lan=en-US&anchor=ht
tps%3A%2F%2Fzaminfoundation.ngo%2Fen%2Fabout&index=1&md5=3977c661221018741b0cade
6f464b7f3
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 08:03:00 EEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom